Anchiano Therapeutics

1 stories about Anchiano Therapeutics
נאסד"ק וול סטריט

Anchiano Therapeutics Stock Falls on Nasdaq IPO

13.02.19|Lilach Baumer
The cancer treatment company priced its ADSs at $11.5 per unit, expecting proceeds of $30.5 million